Parnax Lab revenue climbs 32% to ₹248.54 crore in FY26
The pharmaceutical firm grew annual sales by nearly a third, though bottom-line growth remained muted due to one-time labor code transition costs.
— 1 earlier story on Parnax Lab Ltd. →What's new
- Consolidated revenue rose to ₹248.54 cr from ₹187.74 cr in the prior year.
- Net profit reached ₹11.78 cr after accounting for ₹1.37 cr in labor code transition costs.
- The board re-appointed an independent director with pharmaceutical sector expertise.
Why this matters
Top-line expansion of 32.4% indicates healthy demand for the company's products. However, the flat profit growth suggests that rising operational expenses and one-time transitions are currently absorbing the gains from that scale.
What we're watching
- Whether margins recover in FY27 now that labor code transition costs are behind them.
- The impact of the final quarter's performance dip on the current fiscal year.
- Updates on the company's ability to scale profitability alongside revenue.
The full read
Parnax Lab ended FY26 with ₹248.54 crore in consolidated revenue, a 32.4% increase from the ₹187.74 crore reported in FY25. Despite this expansion, net profit remained flat at ₹11.78 crore. The company faced ₹1.37 crore in exceptional costs tied to the transition to new labor codes, which weighed on the final results. A dip in performance during the fourth quarter also tempered the annual outcome. While the revenue growth is a clear indicator of business expansion, the company must now prove it can convert that scale into higher margins. The re-appointment of an experienced independent director provides continuity at the board level, but the immediate test for the company is reversing the late-year performance slide.
Questions answered
- How did Parnax Lab perform in FY26 compared to the previous year?
- The company grew its consolidated revenue by 32.4% to ₹248.54 crore. Net profit was ₹11.78 crore, showing only marginal growth over the prior year.
- What impacted the company's bottom line this year?
- Profitability was affected by ₹1.37 crore in exceptional costs related to the transition to new labor codes. Additionally, the company experienced a slight dip in performance during the final quarter.
- What governance changes were announced?
- The board confirmed the re-appointment of an independent director. The director brings extensive experience in the pharmaceutical industry.
Story so far
All notes on PARNAXLAB →- 28 May 2026 · 9:00 PM IST Parnax Lab revenue climbs 32% to ₹248.54 crore in FY26
- today Parnax Lab revenue climbs 32% but profit stalls on rising costs